Joseph Lee is a member of GHIC’s investment team, focusing on thesis generation and deal execution. He led GHIC’s investments in Antheia, Cytovale, and Jumpcode, and manages the firm's investments in BugSeq and Biolinq. He also sits on the board of Antheia and Jumpcode. Joseph previously worked at Sender Company and Partners investing in pharmaceutical and biotechnology public equities, and at Great Point Partners on their private equity team. He has a background in medicine, surgery, and global health, and has provided care to medically underserved communities in India and Guatemala. Joseph received his MD from the University of Texas Southwestern Medical Center and was a general surgery resident at the University of Colorado. He also holds an MBA from Harvard Business School.